The results demonstrated that patients with HR+, HER2-metastasizing, and endocrine-therapy-resistant breast cancer had a moderate efficacy and a good safety profile when given pilaralisib or voxtalisib in conjunction with letrozole [88]. The gene discussed is HR; the disease is breast carcinoma.